What is comparable to Cosentyx? Exploring Biologic Alternatives
•
5 min read
Cosentyx (secukinumab), first FDA-approved in 2015 for moderate-to-severe plaque psoriasis, has since been approved for several other conditions including psoriatic arthritis and ankylosing spondylitis. Despite its proven efficacy, many patients and healthcare providers may need to find out **what is comparable to Cosentyx** for a variety of reasons, including effectiveness, side effects, or drug class limitations.
